VTRS
HealthcareViatris Inc.
$12.37
$-0.09 (-0.72%)
Jan 5, 2026
Price History (1Y)
Analysis
Viatris Inc. is a healthcare company operating in the specialty and generic drug manufacturers industry. The company has a significant scale with a market capitalization of $14.28B, revenue of $14.12B, and approximately 30,000 employees. From a financial health perspective, Viatris reported gross margin of 40.1%, operating margin of 10.8%, and profit margin of -26.1%. The company has negative net income, with a loss of $3.69 billion in the trailing twelve months. However, it generated free cash flow of $2.73B and has a current ratio of 1.35. The balance sheet shows debt of $14.77B and cash of $1.16B, resulting in a debt-to-equity ratio of 97.03. In terms of valuation context, Viatris has a forward P/E ratio of 5.02, EV/EBITDA of 6.92, and price to book of 0.94. The company's revenue growth rate is 0.2% year-over-year, while its earnings growth rate is not available. The dividend yield is 385.0%, but the payout ratio is 960.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $14.28B
- P/E Ratio
- N/A
- 52-Week High
- $12.62
- 52-Week Low
- $6.85
- Avg Volume
- 8.37M
- Beta
- 0.79
- Dividend Yield
- 385.00%
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 30,000